Tiamat Sciences, a leading plant-based life sciences company, has achieved a significant milestone in the production of T7 polymerase, a critical enzyme used in mRNA vaccine production. This groundbreaking achievement showcases the potential of harnessing plant-based systems to produce essential reagents, offering unmatched flexibility, scalability, and cost-effectiveness for the rapid development of mRNA vaccines on a global scale. France-Emmanuelle Adil, Co-Founder, and CEO of Tiamat Sciences, expressed excitement about this milestone and highlighted the power of plant-based biotechnology in driving innovation in healthcare.
In addition to T7 polymerase, Tiamat Sciences has successfully expressed human Fibroblast Growth Factor 2 (hFGF2) at a high yield, exceeding 20mg/kg biomass. This achievement opens up possibilities for further optimization to meet the demands of the Regenerative Medicine sector for affordable Cell & Gene therapies.
While Tiamat Sciences does not manufacture vaccines, its reagents play a crucial role in fueling innovation in the healthcare and pharmaceutical industries. By providing essential tools and technologies, Tiamat Sciences enables pharmaceutical companies to accelerate the development and production of life-saving treatments.
Tiamat Sciences is actively seeking strategic co-development partnerships to further advance this technology and expedite the commercialization of plant-based reagents for vaccine production. Their commitment to sustainability, innovation, and global health drives their mission to revolutionize the production of essential biomolecules, ensuring equitable access to life-saving treatments worldwide.
To learn more about Tiamat Sciences and partnership opportunities, visit their website at tiamat-sciences.com.
About Tiamat Sciences:
Tiamat Sciences is a cutting-edge plant-based platform and product life sciences company that is transforming the production of reagents. Through their innovative biotechnology, Tiamat Sciences empowers partners to develop groundbreaking therapies while reducing material costs, accelerating development timelines, and promoting sustainability in the supply chain.
For the latest updates and information on Tiamat Sciences, please check out the source of this article: https://mma.prnewswire.com/media/2412491/Tiamat_Sciences1.jpg?p=original.
Source link
